Longterm Dpp4inhibitor Use Not Tied To Fracture Risk In T2dm | Latest News RSS feed

Longterm Dpp4inhibitor Use Not Tied To Fracture Risk In T2dm - Latest News


Weekly diabetes drug provides similar benefits to daily version

Long-term DPP4-inhibitor use not tied to fracture risk in T2DM More information: Ronald Goldenberg et al. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly ... read more

The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?

59 It is not yet understood whether TAK-875 will lead to long-term ... use of a DPP-4 inhibitor and TAK-875 would be intriguing because it would be completely orally administered and could potentially ... read more

Post-Transplant Hip Fracture Rate Declining

included 69,740 patients who under kidney transplantation from 1997 to 2010. Results showed patients who received a transplant in 2010 had a 44% decreased risk of hip fracture compared with those who ... read more

Looking for another news?


Merck (MRK) Will Present JANUVIA, Diabetes Pipeline, Other Data at 76th Scientific Sessions of the ADA

JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk ... Use caution in a patient with a history ... read more


The Impact of Diabetes and Diabetes Medications on Bone Health

Drugs for the treatment of T2DM may also impact on the risk for fractures. For example, thiazolidinediones accelerate bone loss and increase the risk of fractures, particularly in older women. In cont... read more

Short-term PPIs tied to higher hip fracture risk in Alzheimer's

(HealthDay)—Short-term proton pump inhibitor use, but not long-term or cumulative use, is associated with an increased risk of hip fracture among Alzheimer's patients, according to a study published o... read more

Bolstering your armamentarium with SGLT2 inhibitors

32 Euglycemic ketoacidosis is considered rare, but recent cases have surfaced both in patients with T1DM and T2DM treated with SGLT2 inhibitors (although these agents are not approved for use in T1DM ... read more

Eli Lilly & Co. (LLY) John C. Lechleiter on Q2 2016 Results - Earnings Call Transcript

At ACR, along with Incyte, we presented data for baricitinib in rheumatoid arthritis from the Phase III long-term extension ... that Trajenta, a DPP-4 inhibitor, reduced blood sugar in adults with typ... read more

Prostate Cancer ADT Ups Osteoporotic Fracture Risk

... incident fracture—including 4860 hip fractures—during a follow-up of about 270,300 patient-years. Compared with men who did not have PCa, those who had PCa with ADT had a significant 40% increased ... read more

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

In clinical and real-world studies, canagliflozin, an SGLT2 inhibitor, has demonstrated superior A1C lowering compared to the DPP-4 inhibitor ... may use this article as long as the work is properly c... read more

Sodium-glucose cotransporter-2 inhibitors: Expanding oral treatment options for type 2 diabetes mellitus

A novel class of medications, sodium-glucose cotransporter-2 inhibitors ... T2DM. Patient assistance programs are available for all three SGLT2 inhibitors as well as combination products. Despite thei... read more

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline

Objective: The objective was to develop clinical practice guidelines for the primary prevention of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) in patients at metabolic risk. Concl... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us